Opinion

Video

Shifting Paradigms: Biomarker Testing and ESR1 Mutation Surveillance in HR+ HER2- Breast Cancer

Dr. Clifton and Dr. Gandhi discuss the critical role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer, and its impact on prognosis and treatment decision-making.

Video content above is prompted by the following:

  • Please discuss the role of biomarker testing, particularly ESR1 mutation surveillance, in HR+/HER2- breast cancer.
  • How do the results of these tests influence prognosis and treatment decision-making?
Related Videos
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
5 experts are featured in this series
5 experts are featured in this series